Video

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Author(s):

Tanios Bekaii-Saab, MD
Related Videos
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Kimmie Ng, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Richard Kim, MD
Arvind N. Dasari, MD, MS
Related Content
FDA
October 4th 2024

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

stock.adobe.com
September 27th 2024

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Weiguo Su, PhD
September 24th 2024

Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy

Botensilimab/Baltstilimab in MSS CRC | Image Credit: © Dr_Microbe - stock.adobe.com
September 23rd 2024

GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer